| Year |
Citation |
Score |
| 2020 |
Chodisetti SB, Fike AJ, Domeier PP, Schell SL, Mockus TE, Choi NM, Corradetti C, Hou B, Atkins HM, Caricchio R, Decker T, Lukacher AE, Olsen N, Rahman ZSM. Serine Phosphorylation of the STAT1 Transactivation Domain Promotes Autoreactive B Cell and Systemic Autoimmunity Development. Journal of Immunology (Baltimore, Md. : 1950). PMID 32253245 DOI: 10.4049/Jimmunol.2000170 |
0.355 |
|
| 2020 |
Decker T, Söling U, Hahn A, Maintz C, Kurbacher CM, Vehling-Kaiser U, Sent D, Klare P, Hagen V, Chiabudini M, Falkenstein J, Indorf M, Runkel E, Potthoff K. Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer. Bmc Cancer. 20: 286. PMID 32252684 DOI: 10.1186/S12885-020-06747-Y |
0.304 |
|
| 2020 |
Stickeler E, Harbeck N, Thill M, Nusch A, Chiabudini M, Kruggel L, Jänicke M, Marschner N, Zahn M, Welt A, Wöckel A, Decker T. Abstract P2-17-01: Therapy of advanced breast cancer for patients with hormone receptor-positive/HER2-negative and HER2-positive tumors is changing in real life: First results from the prospective, national research platform OPAL for patients with advanced breast cancer in Germany Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-17-01 |
0.325 |
|
| 2020 |
Wöckel A, Basiora P, Bohlmann M, Decker T, Falbrede J, Fasching P, Forstbauer H, Hesse T, Hoffmann O, Jackisch C, Kaczerowsky A, Lorenz R, Lüdtke-Heckenkamp K, Lüftner D, Marmé F, et al. Abstract P1-19-33: Real-world efficacy of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Second interim analysis from the RIBANNA study Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-19-33 |
0.328 |
|
| 2019 |
Platanitis E, Demiroz D, Schneller A, Fischer K, Capelle C, Hartl M, Gossenreiter T, Müller M, Novatchkova M, Decker T. A molecular switch from STAT2-IRF9 to ISGF3 underlies interferon-induced gene transcription. Nature Communications. 10: 2921. PMID 31266943 DOI: 10.1038/S41467-019-10970-Y |
0.378 |
|
| 2019 |
Decker T, Marschner N, Muendlein A, Welt A, Hagen V, Rauh J, Schröder H, Jaehnig P, Potthoff K, Lerchenmüller C. VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer. Breast Cancer Research and Treatment. PMID 31115844 DOI: 10.1007/S10549-019-05280-2 |
0.314 |
|
| 2019 |
Nandakumar R, Tschismarov R, Meissner F, Prabakaran T, Krissanaprasit A, Farahani E, Zhang BC, Assil S, Martin A, Bertrams W, Holm CK, Ablasser A, Klause T, Thomsen MK, Schmeck B, ... ... Decker T, et al. Intracellular bacteria engage a STING-TBK1-MVB12b pathway to enable paracrine cGAS-STING signalling. Nature Microbiology. PMID 30804548 DOI: 10.1038/S41564-019-0367-Z |
0.334 |
|
| 2019 |
Kollmann S, Grundschober E, Maurer B, Warsch W, Grausenburger R, Edlinger L, Huuhtanen J, Lagger S, Hennighausen L, Valent P, Decker T, Strobl B, Mueller M, Mustjoki S, Hoelbl-Kovacic A, et al. Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia. Leukemia. PMID 30679796 DOI: 10.1038/S41375-018-0369-5 |
0.376 |
|
| 2019 |
Zaiss MR, Uhlig J, Zahn M, Decker T, Lehmann HC, Harde J, Vannier C, Hogrefe C, Marschner N. An observational study to evaluate the potential of Onlife to improve chemotherapy-induced peripheral neuropathy: Final results of the STEFANO trial. Journal of Clinical Oncology. 37: e23143-e23143. DOI: 10.1200/Jco.2019.37.15_Suppl.E23143 |
0.309 |
|
| 2019 |
Wöckel A, Decker T, Fasching PA, Jackisch C, Luftner D, Marme F, Reimer T, Roos C. Real-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Baseline data from the RIBANNA study. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E12520 |
0.301 |
|
| 2019 |
Stahler A, Stintzing S, Modest DP, Jelas I, Heinrich K, Miller-Phillips L, von Einem JC, Vehling-Kaiser U, Decker T, Kiani A, Fischer von Weikersthal L, Heintges T, Kahl C, Kullmann F, Scheithauer W, et al. Association of MAPK signaling subtypes with prognostic benefit for bevacizumab in left-sided metastatic colorectal cancer (mCRC) patients treated with FOLFIRI + cetuximab / bevacizumab (FIRE-3 trial). Journal of Clinical Oncology. 37: 3584-3584. DOI: 10.1200/Jco.2019.37.15_Suppl.3584 |
0.309 |
|
| 2019 |
Rüschoff J, Lebeau A, Kreipe H, Sinn P, Schildhaus H, Decker T, Ammann J, Künzel C, Koch W, Untch M. Abstract P4-02-08: Statistical modeling of influential variables affecting HER2-positivity in breast cancer: Final analyses from two large, multicenter, noninterventional studies in Germany Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P4-02-08 |
0.304 |
|
| 2019 |
Wöckel A, Fasching P, Guderian G, Heim J, Jackisch C, Lück H, Lüftner D, Marmé F, Reimer T, Decker T. Abstract OT3-02-01: RIBANNA — Real-world evidence of ribociclib plus aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line therapy for postmenopausal women with HR+, HER2– advanced breast cancer (aBC) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ot3-02-01 |
0.322 |
|
| 2018 |
Decker T, Denkert C, Lübbe K, Müller V, Mundhenke C, Furlanetto J, Schmidt M, Thill M, Tierbach V, Seither F, Loibl S. Anti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA) GBG 97. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii119. PMID 32136148 DOI: 10.1093/Annonc/Mdy272.352 |
0.314 |
|
| 2018 |
Parrini M, Meissl K, Ola MJ, Lederer T, Puga A, Wienerroither S, Kovarik P, Decker T, Müller M, Strobl B. The C-Terminal Transactivation Domain of STAT1 Has a Gene-Specific Role in Transactivation and Cofactor Recruitment. Frontiers in Immunology. 9: 2879. PMID 30574148 DOI: 10.3389/Fimmu.2018.02879 |
0.348 |
|
| 2018 |
Platanitis E, Decker T. Regulatory Networks Involving STATs, IRFs, and NFκB in Inflammation. Frontiers in Immunology. 9: 2542. PMID 30483250 DOI: 10.3389/Fimmu.2018.02542 |
0.345 |
|
| 2018 |
Szappanos D, Tschismarov R, Perlot T, Westermayer S, Fischer K, Platanitis E, Kallinger F, Novatchkova M, Lassnig C, Müller M, Sexl V, Bennett KL, Foong-Sobis M, Penninger JM, Decker T. The RNA helicase DDX3X is an essential mediator of innate antimicrobial immunity. Plos Pathogens. 14: e1007397. PMID 30475900 DOI: 10.1371/Journal.Ppat.1007397 |
0.31 |
|
| 2018 |
Tesch H, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Peyman H, Janni W, Muth M, Kreuzeder J, et al. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial. International Journal of Cancer. PMID 29992557 DOI: 10.1002/Ijc.31738 |
0.322 |
|
| 2018 |
Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, Clappier E, Decker T, Fajmann S, Fux DA, Greiner G, Gueltekin S, Heller G, Herkner H, Hoermann G, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood. PMID 29907599 DOI: 10.1182/Blood-2017-10-810739 |
0.304 |
|
| 2018 |
Fasching PA, Nusch A, Heinrich B, Brucker S, Decker T, Kurbacher CM, Tesch H, Krabisch P, Mundhenke C, Fehm TN, Janni W, Lueftner D, Schneeweiss A, Schuler MH, Guderian G, et al. RIBECCA: A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole—Results of the first interim analysis. Journal of Clinical Oncology. 36: 1051-1051. DOI: 10.1200/Jco.2018.36.15_Suppl.1051 |
0.304 |
|
| 2018 |
Loibl S, Barinoff J, Seiler S, Decker T, Denkert C, Hardy-Bessard A, Senkus-Konefka E, Cognetti F, Palmieri C, Gelmon K, Luebbe K, Furlanetto J, Mueller V, Mundhenke C, Schmidt M, et al. Abstract OT3-05-04: A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA) Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Ot3-05-04 |
0.33 |
|
| 2018 |
Schmidt M, Decker T, Fehm T, Fuxius S, Harbeck N, Juhasz-Böss I, Thomssen C, Seehase M, Schollenberger L, Ruckes C, Möbus V. Abstract OT2-05-02: A phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR+) / human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy - VinoMetro Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Ot2-05-02 |
0.343 |
|
| 2018 |
Lordick F, Haffner I, Luber B, Maier D, Raimundez E, Hasenauer J, Kretzschmar A, Weikersthal LFv, Ahlborn M, Knorrenschild JR, Siegler G, Rau B, Fuxius S, Decker T, Schierle K, et al. Abstract 2615: Heterogeneity of HER2 expression in gastric cancer (GC) leads to high deviation rates between local and central testing and hampers efficacy of anti-HER2 therapy: Survival results from the VARIANZ study Cancer Research. 78: 2615-2615. DOI: 10.1158/1538-7445.Am2018-2615 |
0.32 |
|
| 2017 |
Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, O'Regan R, Mouret-Reynier MA, Kalev D, Egle D, Csőszi T, Bordonaro R, Decker T, Tjan-Heijnen VCG, Blau S, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology. PMID 29223745 DOI: 10.1016/S1470-2045(17)30688-5 |
0.328 |
|
| 2017 |
Decker T, Overkamp F, Rösel S, Nusch A, Göhler T, Indorf M, Sahlmann J, Trarbach T. A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO). Bmc Cancer. 17: 499. PMID 28743247 DOI: 10.1186/S12885-017-3492-1 |
0.312 |
|
| 2017 |
Kovarik JJ, Kernbauer E, Hölzl MA, Hofer J, Gualdoni GA, Schmetterer KG, Miftari F, Sobanov Y, Meshcheryakova A, Mechtcheriakova D, Witzeneder N, Greiner G, Ohradanova-Repic A, Waidhofer-Söllner P, Säemann MD, ... Decker T, et al. Fasting metabolism modulates the interleukin-12/interleukin-10 cytokine axis. Plos One. 12: e0180900. PMID 28742108 DOI: 10.1371/Journal.Pone.0180900 |
0.321 |
|
| 2017 |
Schramm A, Schochter F, Friedl TWP, de Gregorio N, Andergassen U, Alunni-Fabbroni M, Trapp E, Jaeger B, Heinrich G, Camara O, Decker T, Ober A, Mahner S, Fehm TN, Pantel K, et al. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. Clinical Breast Cancer. 17: 279-285. PMID 28190761 DOI: 10.1016/J.Clbc.2016.11.008 |
0.336 |
|
| 2017 |
Majoros A, Platanitis E, Kernbauer-Hölzl E, Rosebrock F, Müller M, Decker T. Canonical and Non-Canonical Aspects of JAK-STAT Signaling: Lessons from Interferons for Cytokine Responses. Frontiers in Immunology. 8: 29. PMID 28184222 DOI: 10.3389/Fimmu.2017.00029 |
0.394 |
|
| 2017 |
Haffner I, Luber B, Maier D, Kretzschmar A, Weikersthal LFv, Ahlborn M, Riera-Knorrenschild J, Rau B, Weissinger F, Fuxius S, Neumann S, Decker T, Schierle K, Wittekind C, Lordick F. Central validation of HER2 status to determine heterogeneity of marker expression in HER2-positive gastric cancer (GC). Journal of Clinical Oncology. 35: 12-12. DOI: 10.1200/Jco.2017.35.4_Suppl.12 |
0.302 |
|
| 2017 |
Loibl S, Barinoff J, Seiler S, Decker T, Denkert C, Luebbe K, Furlanetto J, Mueller V, Mundhenke C, Schmidt M, Minckwitz Gv, Uhlig M, Burchardi N, Thill M. A randomized, open-label, multicentre, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy based treatment strategy in patients with hormone receptor positive/HER2-negative metastatic breast cancer in a real world setting. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps1115 |
0.326 |
|
| 2017 |
Jackisch C, Fasching PA, Grischke E, Schuetz F, Decker T, Uleer C, Salat C, Foerster F, Schmidt M, Mundhenke C, Tesch H, Wimberger P, Aktas B, Zahn M, Tome O, et al. Median progression free survival (PFS) for patients treated with everolimus (EVE) + exemestane (EXE) for HR+ mBC in routine clinical practice: Results of the 3rd interim analysis of the non-interventional trial BRAWO. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E12547 |
0.305 |
|
| 2017 |
Fasching PA, Grischke E, Schuetz F, Decker T, Uleer C, Salat C, Foerster F, Schmidt M, Mundhenke C, Tesch H, Jackisch C, Wimberger P, Aktas B, Zahn M, Tome O, et al. Analysis of everolimus starting dose as prognostic marker in HR+ mBC patients treated with everolimus (EVE) + exemestane (EXE): Results of the 3rd interim analysis of the non-interventional trial BRAWO. Journal of Clinical Oncology. 35: 1061-1061. DOI: 10.1200/Jco.2017.35.15_Suppl.1061 |
0.315 |
|
| 2017 |
Leo AD, Lee KS, Ciruelos E, Lønning P, Janni W, O'Regan R, Reynier MM, Kalev D, Egle D, Csoszi T, Bordonaro R, Decker T, Tjan-Heijnen V, Blau S, Schirone A, et al. Abstract S4-07: BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-S4-07 |
0.342 |
|
| 2017 |
Fasching P, Decker T, Fehm T, Janni W, Kuemmel S, Lueftner D, Schneeweiss A, Schuler M, Guderian G, Schmidt-Wetzel S, Reiners R, Schubert J, Brucker S. Abstract OT2-01-18: RIBECCA - A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Ot2-01-18 |
0.327 |
|
| 2017 |
Elger T, Decker T, Fehm T, Fuxius S, Harbeck N, Juhasz-Böss I, Möbus V, Thomssen C, Seehase M, Schollenberger L, Ruckes C, Schmidt M. 312TiPVinoMetro: Phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx365.075 |
0.302 |
|
| 2017 |
Thomssen C, Decker T, Fehm T, Fuxius S, Harbeck N, Juhasz-Böss I, Möbus V, Seehase M, Schollenberger L, Ruckes C, Schmidt M. A Phase II Study of Metronomic Daily Oral Vinorelbine as First-Line Chemotherapy in Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer Resistant to Endocrine Therapy: Vinometro The Breast. 36. DOI: 10.1016/S0960-9776(17)30701-4 |
0.302 |
|
| 2016 |
Gamradt P, Xu Y, Gratz N, Duncan K, Kobzik L, Högler S, Kovarik P, Decker T, Jamieson AM. The Influence of Programmed Cell Death in Myeloid Cells on Host Resilience to Infection with Legionella pneumophila or Streptococcus pyogenes. Plos Pathogens. 12: e1006032. PMID 27973535 DOI: 10.1371/Journal.Ppat.1006032 |
0.33 |
|
| 2016 |
Chen TT, Tsai MH, Kung JT, Lin KI, Decker T, Lee CK. STAT1 regulates marginal zone B cell differentiation in response to inflammation and infection with blood-borne bacteria. The Journal of Experimental Medicine. PMID 27849553 DOI: 10.1084/Jem.20151620 |
0.361 |
|
| 2016 |
Martins R, Maier J, Gorki AD, Huber KV, Sharif O, Starkl P, Saluzzo S, Quattrone F, Gawish R, Lakovits K, Aichinger MC, Radic-Sarikas B, Lardeau CH, Hladik A, Korosec A, ... ... Decker T, et al. Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions. Nature Immunology. PMID 27798618 DOI: 10.1038/Ni.3590 |
0.303 |
|
| 2016 |
Putz EM, Majoros A, Gotthardt D, Prchal-Murphy M, Zebedin-Brandl EM, Fux DA, Schlattl A, Schreiber RD, Carotta S, Müller M, Gerner C, Decker T, Sexl V. Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity. Oncoimmunology. 5: e1186314. PMID 27757297 DOI: 10.1080/2162402X.2016.1186314 |
0.349 |
|
| 2016 |
Tortola L, Nitsch R, Bertrand MJ, Kogler M, Redouane Y, Kozieradzki I, Uribesalgo I, Fennell LM, Daugaard M, Klug H, Wirnsberger G, Wimmer R, Perlot T, Sarao R, Rao S, ... ... Decker T, et al. The Tumor Suppressor Hace1 Is a Critical Regulator of TNFR1-Mediated Cell Fate. Cell Reports. PMID 27160902 DOI: 10.1016/J.Celrep.2016.04.032 |
0.337 |
|
| 2016 |
Decker T. Emancipation from transcriptional latency: unphosphorylated STAT5 as guardian of hematopoietic differentiation. The Embo Journal. 35: 555-7. PMID 26893391 DOI: 10.15252/Embj.201693974 |
0.317 |
|
| 2016 |
Majoros A, Platanitis E, Szappanos D, Cheon H, Vogl C, Shukla P, Stark GR, Sexl V, Schreiber R, Schindler C, Müller M, Decker T. Response to interferons and antibacterial innate immunity in the absence of tyrosine-phosphorylated STAT1. Embo Reports. PMID 26882544 DOI: 10.15252/Embr.201540726 |
0.41 |
|
| 2016 |
Schütz F, Grischke E, Decker T, Uleer C, Schneeweiss A, Salat C, Wimberger P, Mundhenke C, Förster F, Kluth-Pepper B, Schubert J, Bloch W, Tesch H, Jackisch C, Lüftner D, et al. Abstract P4-13-08: Stomatitis in patients treated with everolimus and exemestane - Results of the 3rd interim analysis of the non-interventional trial BRAWO Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P4-13-08 |
0.301 |
|
| 2015 |
Berry D, Kuzyk O, Rauch I, Heider S, Schwab C, Hainzl E, Decker T, Müller M, Strobl B, Schleper C, Urich T, Wagner M, Kenner L, Loy A. Intestinal Microbiota Signatures Associated with Inflammation History in Mice Experiencing Recurring Colitis. Frontiers in Microbiology. 6: 1408. PMID 26697002 DOI: 10.3389/Fmicb.2015.01408 |
0.672 |
|
| 2015 |
Hainzl E, Stockinger S, Rauch I, Heider S, Berry D, Lassnig C, Schwab C, Rosebrock F, Milinovich G, Schlederer M, Wagner M, Schleper C, Loy A, Urich T, Kenner L, ... ... Decker T, et al. Intestinal Epithelial Cell Tyrosine Kinase 2 Transduces IL-22 Signals To Protect from Acute Colitis. Journal of Immunology (Baltimore, Md. : 1950). PMID 26432894 DOI: 10.4049/Jimmunol.1402565 |
0.68 |
|
| 2015 |
Untch M, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Thomssen C, Jackisch C, Beckmann MW, Blohmer JU, ... ... Decker T, et al. Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). Geburtshilfe Und Frauenheilkunde. 75: 556-565. PMID 26166836 DOI: 10.1055/S-0035-1546120 |
0.303 |
|
| 2015 |
Wienerroither S, Shukla P, Farlik M, Majoros A, Stych B, Vogl C, Cheon H, Stark GR, Strobl B, Müller M, Decker T. Cooperative Transcriptional Activation of Antimicrobial Genes by STAT and NF-κB Pathways by Concerted Recruitment of the Mediator Complex. Cell Reports. 12: 300-12. PMID 26146080 DOI: 10.1016/J.Celrep.2015.06.021 |
0.353 |
|
| 2015 |
Abdul-Sater AA, Majoros A, Plumlee CR, Perry S, Gu AD, Lee C, Shresta S, Decker T, Schindler C. Different STAT Transcription Complexes Drive Early and Delayed Responses to Type I IFNs. Journal of Immunology (Baltimore, Md. : 1950). 195: 210-6. PMID 26019270 DOI: 10.4049/Jimmunol.1401139 |
0.375 |
|
| 2015 |
Rauch I, Rosebrock F, Hainzl E, Heider S, Majoros A, Wienerroither S, Strobl B, Stockinger S, Kenner L, Müller M, Decker T. Noncanonical Effects of IRF9 in Intestinal Inflammation: More than Type I and Type III Interferons. Molecular and Cellular Biology. 35: 2332-43. PMID 25918247 DOI: 10.1128/Mcb.01498-14 |
0.704 |
|
| 2015 |
Berry D, Mader E, Lee TK, Woebken D, Wang Y, Zhu D, Palatinszky M, Schintlmeister A, Schmid MC, Hanson BT, Shterzer N, Mizrahi I, Rauch I, Decker T, Bocklitz T, et al. Tracking heavy water (D2O) incorporation for identifying and sorting active microbial cells. Proceedings of the National Academy of Sciences of the United States of America. 112: E194-203. PMID 25550518 DOI: 10.1073/Pnas.1420406112 |
0.665 |
|
| 2015 |
Stintzing S, Modest DP, Weikersthal LFv, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S, Heintges T, Lerchenmuller CA, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, et al. Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Journal of Clinical Oncology. 33: 515-515. DOI: 10.1200/Jco.2015.33.3_Suppl.515 |
0.315 |
|
| 2015 |
Michl M, Weikersthal LFv, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S, Heintges T, Lerchenmueller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, et al. Baseline carcinoembryonic antigen (CEA) serum levels to predict bevacizumab-based treatment response in patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving 1st-line therapy with FOLFIRI plus cetuximab or bevacizumab (AIO KRK0306, FIRE3 trial). Journal of Clinical Oncology. 33: 3581-3581. DOI: 10.1200/Jco.2015.33.15_Suppl.3581 |
0.302 |
|
| 2015 |
Jackisch C, Grischke E, Schneeweiss A, Decker T, Uleer C, Förster F, Tomé O, Wimberger P, Kurbacher CM, Mueller B, Harbeck N, Mundhenke C, Kuemmel S, Muth M, Kreuzeder J, et al. Abstract P5-19-12: Subgroup analysis on efficacy in the routine treatment - Results of the 2nd interim analysis of BRAWO, the non-interventional trial "Breast Cancer Treatment with Everolimus and Exemestane for HR+ Women" Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-19-12 |
0.338 |
|
| 2015 |
Tesch H, Stoetzer OJ, Decker T, Kurbacher CM, Neumeister R, Marmé F, Schneeweis A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lueftner D, Hadji P, Janni W, Muth M, et al. Abstract P5-19-06: 4EVER - Final efficacy analysis of the phase IIIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE) Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-19-06 |
0.332 |
|
| 2015 |
Jaeger BA, Andergassen U, Neugebauer JK, Alunni-Fabbroni M, Melcher CA, Hagenbeck C, Albrecht S, Lorenz R, Decker T, Heinrich G, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Friese K, et al. Abstract P4-01-08: Persistence of circulating tumor cells immediately after and two years after systemic adjuvant chemotherapy in patients with early breast cancer – Results of the German SUCCESS trials Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-01-08 |
0.318 |
|
| 2015 |
Wienerroither S, Shukla P, Farlik M, Majoros A, Vogl C, Cheon H, Stark G, Strobl B, Müller M, Decker T. ID: 54 Cytokine. 76: 74. DOI: 10.1016/J.Cyto.2015.08.084 |
0.376 |
|
| 2014 |
Luu K, Greenhill CJ, Majoros A, Decker T, Jenkins BJ, Mansell A. STAT1 plays a role in TLR signal transduction and inflammatory responses. Immunology and Cell Biology. 92: 761-9. PMID 25027037 DOI: 10.1038/Icb.2014.51 |
0.371 |
|
| 2014 |
Rauch I, Hainzl E, Rosebrock F, Heider S, Schwab C, Berry D, Stoiber D, Wagner M, Schleper C, Loy A, Urich T, Müller M, Strobl B, Kenner L, Decker T. Type I interferons have opposing effects during the emergence and recovery phases of colitis. European Journal of Immunology. 44: 2749-60. PMID 24975266 DOI: 10.1002/Eji.201344401 |
0.707 |
|
| 2014 |
Hansen K, Prabakaran T, Laustsen A, Jørgensen SE, Rahbæk SH, Jensen SB, Nielsen R, Leber JH, Decker T, Horan KA, Jakobsen MR, Paludan SR. Listeria monocytogenes induces IFNβ expression through an IFI16-, cGAS- and STING-dependent pathway. The Embo Journal. 33: 1654-66. PMID 24970844 DOI: 10.15252/Embj.201488029 |
0.329 |
|
| 2014 |
Semper C, Leitner NR, Lassnig C, Parrini M, Mahlakõiv T, Rammerstorfer M, Lorenz K, Rigler D, Müller S, Kolbe T, Vogl C, Rülicke T, Staeheli P, Decker T, Müller M, et al. STAT1β is not dominant negative and is capable of contributing to gamma interferon-dependent innate immunity. Molecular and Cellular Biology. 34: 2235-48. PMID 24710278 DOI: 10.1128/Mcb.00295-14 |
0.381 |
|
| 2014 |
Begitt A, Droescher M, Meyer T, Schmid CD, Baker M, Antunes F, Knobeloch KP, Owen MR, Naumann R, Decker T, Vinkemeier U. STAT1-cooperative DNA binding distinguishes type 1 from type 2 interferon signaling. Nature Immunology. 15: 168-76. PMID 24413774 DOI: 10.1038/Ni.2794 |
0.34 |
|
| 2014 |
Schwab C, Berry D, Rauch I, Rennisch I, Ramesmayer J, Hainzl E, Heider S, Decker T, Kenner L, Müller M, Strobl B, Wagner M, Schleper C, Loy A, Urich T. Longitudinal study of murine microbiota activity and interactions with the host during acute inflammation and recovery. The Isme Journal. 8: 1101-14. PMID 24401855 DOI: 10.1038/Ismej.2013.223 |
0.676 |
|
| 2014 |
Wienerroither S, Rauch I, Rosebrock F, Jamieson AM, Bradner J, Muhar M, Zuber J, Müller M, Decker T. Regulation of NO synthesis, local inflammation, and innate: Immunity to pathogens by BET family proteins Molecular and Cellular Biology. 34: 415-427. PMID 24248598 DOI: 10.1128/Mcb.01353-13 |
0.701 |
|
| 2014 |
Lueftner D, Schuetz F, Grischke E, Fasching PA, Wimberger P, Foerster FG, Decker T, Uleer C, Muth M, Kreuzeder J, Bloch W, Tesch H, Jackisch C. Breast cancer treatment with everolimus and exemestane for ER+ women: Results of the first interim analysis of the noninterventional trial BRAWO. Journal of Clinical Oncology. 32: 578-578. DOI: 10.1200/Jco.2014.32.15_Suppl.578 |
0.323 |
|
| 2014 |
Fasching PA, Decker T, Schneeweiss A, Uleer C, Förster F, Wimberger P, Kurbacher CM, Harbeck N, Tomé O, Müller B, Mundhenke C, Kümmel S, Muth M, Kreuzeder J, Bloch W, et al. Lba9Breast Cancer Treatment With Everolimus And Exemestane For Er+ Women - Results Of The 2Nd Interim Analysis Of The Non-Interventional Trial Brawo Annals of Oncology. 25. DOI: 10.1093/Annonc/Mdu438.6 |
0.314 |
|
| 2014 |
Parrini M, Semper C, Leitner NR, Lassnig C, Vogl C, Wienerroither S, Decker T, Müller M, Strobl B. 144: STAT1 isoforms in transcriptional control – Distinct traits Cytokine. 70: 62-63. DOI: 10.1016/J.Cyto.2014.07.151 |
0.392 |
|
| 2013 |
Rauch I, Müller M, Decker T. The regulation of inflammation by interferons and their STATs. Jak-Stat. 2: e23820. PMID 24058799 DOI: 10.4161/jkst.23820 |
0.672 |
|
| 2013 |
Kernbauer E, Maier V, Rauch I, Müller M, Decker T. Route of Infection Determines the Impact of Type I Interferons on Innate Immunity to Listeria monocytogenes. Plos One. 8: e65007. PMID 23840314 DOI: 10.1371/Journal.Pone.0065007 |
0.648 |
|
| 2013 |
Berry D, Stecher B, Schintlmeister A, Reichert J, Brugiroux S, Wild B, Wanek W, Richter A, Rauch I, Decker T, Loy A, Wagner M. Host-compound foraging by intestinal microbiota revealed by single-cell stable isotope probing. Proceedings of the National Academy of Sciences of the United States of America. 110: 4720-5. PMID 23487774 DOI: 10.1073/Pnas.1219247110 |
0.662 |
|
| 2013 |
Schochter F, Andergassen U, Neugebauer JK, Friedl TWP, Pestka A, Jueckstock JK, Jaeger B, Salmen JC, Hepp PG, Heinrich G, Camara O, Decker T, Ober A, Fehm TN, Pantel K, et al. Prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy in patients with HER2-negative early breast cancer (EBC). Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E22075 |
0.322 |
|
| 2013 |
Fasching PA, Gumbrecht W, Fehm TN, Haeberle L, Muth M, Sickert D, Pugia M, Friedrich K, Matzas M, Lueftner D, Beckmann MW, Hadji P, Kreuzeder J, Lux MP, Janni W, ... ... Decker T, et al. 4EVER: Assessment of circulating tumor cells with a novel, filtration-based method, in a phase IIIb multicenter study for postmenopausal, HER2- negative, estrogen receptor-positive, advanced breast cancer patients. Journal of Clinical Oncology. 31: 591-591. DOI: 10.1200/Jco.2013.31.15_Suppl.591 |
0.322 |
|
| 2013 |
Schochter F, Andergassen U, Neugebauer J, Friedl T, Pestka A, Jueckstock J, Jaeger B, Salmen J, Hepp P, Heinrich G, Camara O, Decker T, Ober A, Fehm T, Pantel K, et al. Abstract P3-12-09: The prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy with and without anthracyclines in patients with HER2-negative early breast cancer (EBC) Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P3-12-09 |
0.323 |
|
| 2013 |
Tesch H, Fasching P, Hadji P, Lueftner D, Janni W, Lux M, Schneeweiss A, Decker T, Belleville E, Kreuzeder J, Muth M, Wallwiener D. Abstract OT2-6-09: 4EVER - A phase IIIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE) Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Ot2-6-09 |
0.332 |
|
| 2012 |
Berry D, Schwab C, Milinovich G, Reichert J, Ben Mahfoudh K, Decker T, Engel M, Hai B, Hainzl E, Heider S, Kenner L, Müller M, Rauch I, Strobl B, Wagner M, et al. Phylotype-level 16S rRNA analysis reveals new bacterial indicators of health state in acute murine colitis. The Isme Journal. 6: 2091-106. PMID 22572638 DOI: 10.1038/Ismej.2012.39 |
0.682 |
|
| 2012 |
Aubry C, Corr SC, Wienerroither S, Goulard C, Jones R, Jamieson AM, Decker T, O'Neill LA, Dussurget O, Cossart P. Both TLR2 and TRIF contribute to interferon-β production during Listeria infection. Plos One. 7: e33299. PMID 22432012 DOI: 10.1371/Journal.Pone.0033299 |
0.325 |
|
| 2012 |
Farlik M, Rapp B, Marie I, Levy DE, Jamieson AM, Decker T. Contribution of a TANK-binding kinase 1-interferon (IFN) regulatory factor 7 pathway to IFN-γ-induced gene expression. Molecular and Cellular Biology. 32: 1032-43. PMID 22252317 DOI: 10.1128/Mcb.06021-11 |
0.389 |
|
| 2012 |
Wallner B, Leitner NR, Vielnascher RM, Kernbauer E, Kolbe T, Karaghiosoff M, Rülicke T, Decker T, Müller M. Generation of mice with a conditional Stat1 null allele. Transgenic Research. 21: 217-24. PMID 21553074 DOI: 10.1007/S11248-011-9519-5 |
0.399 |
|
| 2012 |
Jaeger B, Rack B, Andergassen U, Neugebauer J, Melcher C, Scholz C, Hagenbeck C, Schueller K, Lorenz R, Decker T, Heinrich G, Fehm T, Schneeweiss A, Lichtenegger W, Beckmann M, et al. Abstract P2-01-02: Circulating Tumor Cells (CTC) may Express HER2/neu in Patients With Early HER2/neu Negative Breast Cancer – Results of the German SUCCESS C Trial Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P2-01-02 |
0.308 |
|
| 2011 |
Kastner R, Dussurget O, Archambaud C, Kernbauer E, Soulat D, Cossart P, Decker T. LipA, a tyrosine and lipid phosphatase involved in the virulence of Listeria monocytogenes. Infection and Immunity. 79: 2489-98. PMID 21444667 DOI: 10.1128/Iai.05073-11 |
0.331 |
|
| 2011 |
Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Förster I, Farlik M, Decker T, Du Pasquier RA, Romero P, Tschopp J. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity. 34: 213-23. PMID 21349431 DOI: 10.1016/J.Immuni.2011.02.006 |
0.337 |
|
| 2011 |
Bourgeois C, Majer O, Frohner IE, Lesiak-Markowicz I, Hildering KS, Glaser W, Stockinger S, Decker T, Akira S, Müller M, Kuchler K. Conventional dendritic cells mount a type I IFN response against Candida spp. requiring novel phagosomal TLR7-mediated IFN-β signaling. Journal of Immunology (Baltimore, Md. : 1950). 186: 3104-12. PMID 21282509 DOI: 10.4049/Jimmunol.1002599 |
0.37 |
|
| 2011 |
Hainzl E, Rauch I, Heider S, Kenner L, Decker T, Strobl B, Müller M. PS1-059 Tyrosine kinase 2 protects from chemically-induced colitis via amplification of interleukin-22 signalling Cytokine. 56: 32. DOI: 10.1016/J.Cyto.2011.07.089 |
0.659 |
|
| 2010 |
Farlik M, Reutterer B, Schindler C, Greten F, Vogl C, Müller M, Decker T. Nonconventional initiation complex assembly by STAT and NF-kappaB transcription factors regulates nitric oxide synthase expression. Immunity. 33: 25-34. PMID 20637660 DOI: 10.1016/J.Immuni.2010.07.001 |
0.34 |
|
| 2009 |
Plumlee CR, Lee C, Beg AA, Decker T, Shuman HA, Schindler C. Interferons direct an effective innate response to Legionella pneumophila infection. The Journal of Biological Chemistry. 284: 30058-66. PMID 19720834 DOI: 10.1074/Jbc.M109.018283 |
0.366 |
|
| 2009 |
Maldonado RA, Soriano MA, Perdomo LC, Sigrist K, Irvine DJ, Decker T, Glimcher LH. Control of T helper cell differentiation through cytokine receptor inclusion in the immunological synapse. The Journal of Experimental Medicine. 206: 877-92. PMID 19349465 DOI: 10.1084/Jem.20082900 |
0.339 |
|
| 2009 |
Putz EM, Zebedin E, Csiszar A, Prchal M, Berger A, Decker T, Kovarik P, Sexl V. Unexpected role of STAT1 serine727 for NK cell function Bmc Pharmacology. 9: 1-2. DOI: 10.1186/1471-2210-9-S2-A29 |
0.371 |
|
| 2008 |
Stockinger S, Decker T. Novel functions of type I interferons revealed by infection studies with Listeria monocytogenes. Immunobiology. 213: 889-97. PMID 18926303 DOI: 10.1016/J.Imbio.2008.07.020 |
0.318 |
|
| 2008 |
Soulat D, Bürckstümmer T, Westermayer S, Goncalves A, Bauch A, Stefanovic A, Hantschel O, Bennett KL, Decker T, Superti-Furga G. The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response. The Embo Journal. 27: 2135-46. PMID 18583960 DOI: 10.1038/Emboj.2008.126 |
0.377 |
|
| 2008 |
Zwaferink H, Stockinger S, Hazemi P, Lemmens-Gruber R, Decker T. IFN-beta increases listeriolysin O-induced membrane permeabilization and death of macrophages. Journal of Immunology (Baltimore, Md. : 1950). 180: 4116-23. PMID 18322222 DOI: 10.4049/Jimmunol.180.6.4116 |
0.313 |
|
| 2008 |
Huber M, Steinwald V, Guralnik A, Brüstle A, Kleemann P, Rosenplänter C, Decker T, Lohoff M. IL-27 inhibits the development of regulatory T cells via STAT3. International Immunology. 20: 223-34. PMID 18156621 DOI: 10.1093/Intimm/Dxm139 |
0.31 |
|
| 2008 |
Putz EM, Zebedin-Brandl E, Prchal M, Decker T, Kovarik P, Sexl V. STAT1 Ser727 – key regulator for NK cell-mediated cytotoxicity and tumor surveillance Bmc Pharmacology. 8: 1-1. DOI: 10.1186/1471-2210-8-S1-A27 |
0.346 |
|
| 2007 |
Werts C, le Bourhis L, Liu J, Magalhaes JG, Carneiro LA, Fritz JH, Stockinger S, Balloy V, Chignard M, Decker T, Philpott DJ, Ma X, Girardin SE. Nod1 and Nod2 induce CCL5/RANTES through the NF-kappaB pathway. European Journal of Immunology. 37: 2499-508. PMID 17705131 DOI: 10.1002/Eji.200737069 |
0.382 |
|
| 2007 |
Ramsauer K, Farlik M, Zupkovitz G, Seiser C, Kröger A, Hauser H, Decker T. Distinct modes of action applied by transcription factors STAT1 and IRF1 to initiate transcription of the IFN-gamma-inducible gbp2 gene. Proceedings of the National Academy of Sciences of the United States of America. 104: 2849-54. PMID 17293456 DOI: 10.1073/Pnas.0610944104 |
0.325 |
|
| 2007 |
Pilz A, Kratky W, Decker T. 122 Regulation of Adaptive Immunity by Type I Interferons and Serine-phosphorylated STAT1 Cytokine. 39: 33-34. DOI: 10.1016/J.Cyto.2007.07.127 |
0.327 |
|
| 2005 |
Decker T, Müller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nature Reviews. Immunology. 5: 675-87. PMID 16110316 DOI: 10.1038/Nri1684 |
0.357 |
|
| 2004 |
Stockinger S, Reutterer B, Schaljo B, Schellack C, Brunner S, Materna T, Yamamoto M, Akira S, Taniguchi T, Murray PJ, Müller M, Decker T. IFN regulatory factor 3-dependent induction of type I IFNs by intracellular bacteria is mediated by a TLR- and Nod2-independent mechanism. Journal of Immunology (Baltimore, Md. : 1950). 173: 7416-25. PMID 15585867 DOI: 10.4049/Jimmunol.173.12.7416 |
0.358 |
|
| 2004 |
Decker T. Sepsis: Avoiding its deadly toll Journal of Clinical Investigation. 113: 1387-1389. PMID 15146235 DOI: 10.1172/Jci21819 |
0.324 |
|
| 2004 |
Wanner K, Hipp S, Peschel C, Decker T. MTOR (mammalian target of rapamycin) inhibition with RAD001 induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitizes DLBCL cells to rituximab therapy. Blood. 104: 4620-4620. DOI: 10.1182/Blood.V104.11.4620.4620 |
0.312 |
|
| 2003 |
Varinou L, Ramsauer K, Karaghiosoff M, Kolbe T, Pfeffer K, Müller M, Decker T. Phosphorylation of the Stat1 Transactivation Domain Is Required for Full-Fledged IFN-γ-Dependent Innate Immunity Immunity. 19: 793-802. PMID 14670297 DOI: 10.1016/S1074-7613(03)00322-4 |
0.396 |
|
| 2003 |
Karaghiosoff M, Steinborn R, Kovarik P, Kriegshäuser G, Baccarini M, Donabauer B, Reichart U, Kolbe T, Bogdan C, Leanderson T, Levy D, Decker T, Müller M. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nature Immunology. 4: 471-477. PMID 12679810 DOI: 10.1038/Ni910 |
0.328 |
|
| 2003 |
Pilz A, Ramsauer K, Heidari H, Leitges M, Kovarik P, Decker T. Phosphorylation of the Stat1 transactivating domain is required for the response to type I interferons Embo Reports. 4: 368-373. PMID 12671680 DOI: 10.1038/Sj.Embor.Embor802 |
0.361 |
|
| 2002 |
Stockinger S, Materna T, Stoiber D, Bayr L, Steinborn R, Kolbe T, Unger H, Chakraborty T, Levy DE, Müller M, Decker T. Production of type I IFN sensitizes macrophages to cell death induced by Listeria monocytogenes Journal of Immunology. 169: 6522-6529. PMID 12444163 DOI: 10.4049/Jimmunol.169.11.6522 |
0.371 |
|
| 2002 |
Ramsauer K, Sadzak I, Porras A, Pilz A, Nebreda AR, Decker T, Kovarik P. p38 MAPK enhances STAT1-dependent transcription independently of Ser-727 phosphorylation. Proceedings of the National Academy of Sciences of the United States of America. 99: 12859-64. PMID 12232043 DOI: 10.1073/Pnas.192264999 |
0.361 |
|
| 2002 |
Decker T, Stockinger S, Karaghiosoff M, Müller M, Kovarik P. IFNs and STATs in innate immunity to microorganisms Journal of Clinical Investigation. 109: 1271-1277. PMID 12021240 DOI: 10.1172/Jci15770 |
0.385 |
|
| 2001 |
Woldman I, Varinou L, Ramsauer K, Rapp B, Decker T. The Stat1 binding motif of the interferon-gamma receptor is sufficient to mediate Stat5 activation and its repression by SOCS3. The Journal of Biological Chemistry. 276: 45722-8. PMID 11577084 DOI: 10.1074/Jbc.M105320200 |
0.379 |
|
| 2001 |
Kovarik P, Mangold M, Ramsauer K, Heidari H, Steinborn R, Zotter A, Levy DE, Müller M, Decker T. Specificity of signaling by STAT1 depends on SH2 and C-terminal domains that regulate Ser727 phosphorylation, differentially affecting specific target gene expression Embo Journal. 20: 91-100. PMID 11226159 DOI: 10.1093/Emboj/20.1.91 |
0.34 |
|
| 2001 |
Stoiber D, Stockinger S, Steinlein P, Kovarik J, Decker T. Listeria monocytogenes modulates macrophage cytokine responses through STAT serine phosphorylation and the induction of suppressor of cytokine signaling 3. Journal of Immunology. 166: 466-472. PMID 11123325 DOI: 10.4049/Jimmunol.166.1.466 |
0.401 |
|
| 2000 |
Karaghiosoff M, Neubauer H, Lassnig C, Kovarik P, Schindler H, Pircher H, McCoy B, Bogdan C, Decker T, Brem G, Pfeffer K, Müller M. Partial Impairment of Cytokine Responses in Tyk2-Deficient Mice Immunity. 13: 549-560. PMID 11070173 DOI: 10.1016/S1074-7613(00)00054-6 |
0.344 |
|
| 2000 |
Lafont V, Decker T, Cantrell D. Antigen receptor signal transduction: Activating and inhibitory antigen receptors regulate STAT1 serine phosphorylation European Journal of Immunology. 30: 1851-1860. PMID 10940874 DOI: 10.1002/1521-4141(200007)30:7<1851::Aid-Immu1851>3.0.Co;2-C |
0.309 |
|
| 2000 |
Decker T, Kovarik P. Serine phosphorylation of STATs Oncogene. 19: 2628-2637. PMID 10851062 DOI: 10.1038/Sj.Onc.1203481 |
0.307 |
|
| 2000 |
Kovarik P, Stoiber D, Eyers PA, Menghini R, Neininger A, Gaestel M, Cohen P, Decker T. Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma uses a different signaling pathway. Proceedings of the National Academy of Sciences of the United States of America. 96: 13956-61. PMID 10570180 DOI: 10.1073/Pnas.96.24.13956 |
0.338 |
|
| 2000 |
Kieslinger M, Woldman I, Moriggl R, Hofmann J, Marine J, Ihle JN, Beug H, Decker T. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation Genes & Development. 14: 232-244. DOI: 10.1101/Gad.14.2.232 |
0.302 |
|
| 1999 |
Decker T, Kovarik P. Transcription factor activity of STAT proteins: Structural requirements and regulation by phosphorylation and interacting proteins Cellular and Molecular Life Sciences. 55: 1535-1546. PMID 10526571 DOI: 10.1007/S000180050393 |
0.328 |
|
| 1999 |
Takaoka A, Tanaka N, Mitani Y, Miyazaki T, Fujii H, Sato M, Kovarik P, Decker T, Schlessinger J, Taniguchi T. Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN-gamma, but not IFN-alpha, signaling. The Embo Journal. 18: 2480-8. PMID 10228162 DOI: 10.1093/Emboj/18.9.2480 |
0.359 |
|
| 1998 |
Kovarik P, Stoiber D, Novy M, Decker T. Stat1 combines signals derived from IFN-γ and LPS receptors during macrophage activation Embo Journal. 17: 3660-3668. PMID 9649436 DOI: 10.1093/Emboj/17.13.3660 |
0.361 |
|
| 1998 |
Barahmand-Pour F, Meinke A, Groner B, Decker T. Jak2-Stat5 interactions analyzed in yeast Journal of Biological Chemistry. 273: 12567-12575. PMID 9575217 DOI: 10.1074/Jbc.273.20.12567 |
0.319 |
|
| 1997 |
Decker T, Meinke A. Jaks, Stats and the immune system Immunobiology. 198: 99-111. PMID 9442382 DOI: 10.1016/S0171-2985(97)80031-9 |
0.359 |
|
| 1997 |
Wong AHT, Ning Tam NW, Yang YL, Cuddihy AR, Li S, Kirchhoff S, Hauser H, Decker T, Koromilas AE. Physical association between STAT1 and the interferon-inducible protein kinase PKR and implications for interferon and double-stranded RNA signaling pathways Embo Journal. 16: 1291-1304. PMID 9135145 DOI: 10.1093/Emboj/16.6.1291 |
0.36 |
|
| 1997 |
Decker T, Kovarik P, Meinke A. GAS elements: A few nucleotides with a major impact on cytokine-induced gene expression Journal of Interferon and Cytokine Research. 17: 121-134. PMID 9085936 DOI: 10.1089/Jir.1997.17.121 |
0.335 |
|
| 1996 |
Meinke A, Barahmand-Pour F, Wöhrl S, Stoiber D, Decker T. Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons. Molecular and Cellular Biology. 16: 6937-6944. PMID 8943349 DOI: 10.1128/Mcb.16.12.6937 |
0.381 |
|
| 1996 |
Mellitzer G, Wessely O, Decker T, Meinke A, Hayman MJ, Beug H. Activation of Stat 5b in erythroid progenitors correlates with the ability of ErbB to induce sustained cell proliferation Proceedings of the National Academy of Sciences of the United States of America. 93: 9600-9605. PMID 8790376 DOI: 10.1073/Pnas.93.18.9600 |
0.318 |
|
| 1996 |
Barahmand-pour F, Meinke A, Kieslinger M, Eilers A, Decker T. A Role for STAT Family Transcription Factors in Myeloid Differentiation Current Topics in Microbiology and Immunology. 211: 121-128. PMID 8585942 DOI: 10.1007/978-3-642-85232-9_12 |
0.333 |
|
| 1995 |
Eilers A, Decker T. Activity of Stat family transcription factors is developmentally controlled in cells of the macrophage lineage Immunobiology. 193: 328-333. PMID 8530162 DOI: 10.1016/S0171-2985(11)80562-0 |
0.354 |
|
| 1995 |
Barahmand-pour F, Meinke A, Eilers A, Gouilleux F, Groner B, Decker T. Colony-stimulating factors and interferon-γ activate a protein related to MGF-Stat 5 to cause formation of the differentiation-induced factor in myeloid cells Febs Letters. 360: 29-33. PMID 7875295 DOI: 10.1016/0014-5793(95)00072-H |
0.359 |
|
| 1995 |
Eilers A, Georgellis D, Klose B, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Decker T. Differentiation-regulated serine phosphorylation of STAT1 promotes GAF activation in macrophages. Molecular and Cellular Biology. 15: 3579-3586. PMID 7791765 DOI: 10.1128/Mcb.15.7.3579 |
0.365 |
|
| 1994 |
Rothman P, Kreider B, Azam M, Levy D, Wegenka U, Eilers A, Decker T, Horn F, Kashleva H, Ihle J, Schindler C. Cytokines and Growth factors signal through tyrosine phosphorylation of a family of related transcription factors Immunity. 1: 457-468. PMID 7895157 DOI: 10.1016/1074-7613(94)90088-4 |
0.33 |
|
| 1994 |
Eilers A, Baccarini M, Horn F, Hipskind RA, Schindler C, Decker T. A factor induced by differentiation signals in cells of the macrophage lineage binds to the gamma interferon activation site. Molecular and Cellular Biology. 14: 1364-1373. PMID 7507205 DOI: 10.1128/mcb.14.2.1364-1373.1994 |
0.327 |
|
| 1992 |
Flohr T, Buwitt U, Bonnekoh B, Decker T, Bottger EC. Interferon- γ regulates expression of a novel keratin classe I gene European Journal of Immunology. 22: 975-979. PMID 1372562 DOI: 10.1002/Eji.1830220415 |
0.35 |
|
| Show low-probability matches. |